MX348815B - Metodo para preparar clorhidrato de 1-(4-(4-(3,4-dicloro-2-fluorof enilamino)-7-metoxiquinazolin-6-iloxi)piperidin-1-il)-prop-2-en-1 -ona e intermediarios usados en el mismo. - Google Patents

Metodo para preparar clorhidrato de 1-(4-(4-(3,4-dicloro-2-fluorof enilamino)-7-metoxiquinazolin-6-iloxi)piperidin-1-il)-prop-2-en-1 -ona e intermediarios usados en el mismo.

Info

Publication number
MX348815B
MX348815B MX2014003959A MX2014003959A MX348815B MX 348815 B MX348815 B MX 348815B MX 2014003959 A MX2014003959 A MX 2014003959A MX 2014003959 A MX2014003959 A MX 2014003959A MX 348815 B MX348815 B MX 348815B
Authority
MX
Mexico
Prior art keywords
methoxyquinazolin
fluorophenylamino
yloxy
piperidin
prop
Prior art date
Application number
MX2014003959A
Other languages
English (en)
Other versions
MX2014003959A (es
Inventor
Chan Bang Keuk
Ho Moon Young
Kil Chang Young
Original Assignee
Hanmi Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48044309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX348815(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Science Co Ltd filed Critical Hanmi Science Co Ltd
Publication of MX2014003959A publication Critical patent/MX2014003959A/es
Publication of MX348815B publication Critical patent/MX348815B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a un método mejorado para preparar clorhidrato de 1-(4-(4-(3,4-dicloro-2- fluorofenilamino)-7-metoxiquinazolin-6-iloxi)piperidin-1-il)-prop -2-en-1-ona, que inhibe en forma selectiva y eficaz el crecimiento de las células cancerosas inducidas por la sobreexpresión de un receptor del factor de crecimiento epidérmico (EGFR) y previne el desarrollo de resistencia a fármacos causado por la mutación de una tirosina quinasa, y los intermediarios usados en el mismo.
MX2014003959A 2011-10-05 2012-10-05 Metodo para preparar clorhidrato de 1-(4-(4-(3,4-dicloro-2-fluorof enilamino)-7-metoxiquinazolin-6-iloxi)piperidin-1-il)-prop-2-en-1 -ona e intermediarios usados en el mismo. MX348815B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110101422A KR101272613B1 (ko) 2011-10-05 2011-10-05 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온 염산염의 제조 방법 및 이에 사용되는 중간체
PCT/KR2012/008077 WO2013051883A2 (en) 2011-10-05 2012-10-05 Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)-prop-2-en-1-one hydrochloride and intermediates used therein

Publications (2)

Publication Number Publication Date
MX2014003959A MX2014003959A (es) 2014-05-14
MX348815B true MX348815B (es) 2017-06-30

Family

ID=48044309

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014003959A MX348815B (es) 2011-10-05 2012-10-05 Metodo para preparar clorhidrato de 1-(4-(4-(3,4-dicloro-2-fluorof enilamino)-7-metoxiquinazolin-6-iloxi)piperidin-1-il)-prop-2-en-1 -ona e intermediarios usados en el mismo.

Country Status (23)

Country Link
US (1) US8859767B2 (es)
EP (2) EP2763981B1 (es)
JP (1) JP5805880B2 (es)
KR (1) KR101272613B1 (es)
CN (2) CN110003174A (es)
AU (1) AU2012319291B2 (es)
BR (1) BR112014007718B1 (es)
CA (1) CA2850055C (es)
CY (1) CY1122758T1 (es)
DK (1) DK2763981T3 (es)
ES (1) ES2775197T3 (es)
HR (1) HRP20200426T1 (es)
HU (1) HUE048798T2 (es)
IL (3) IL231911B (es)
IN (1) IN2014DN03447A (es)
LT (1) LT2763981T (es)
MX (1) MX348815B (es)
PL (1) PL2763981T3 (es)
PT (1) PT2763981T (es)
RS (1) RS60118B1 (es)
RU (1) RU2563630C1 (es)
SI (1) SI2763981T1 (es)
WO (1) WO2013051883A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
KR20140096571A (ko) * 2013-01-28 2014-08-06 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
CN104513229A (zh) * 2013-09-28 2015-04-15 正大天晴药业集团股份有限公司 喹唑啉衍生物及其制备方法
CN107406430B (zh) 2015-03-20 2019-04-26 正大天晴药业集团股份有限公司 喹唑啉衍生物的盐及其制备方法
MX2021002875A (es) * 2018-09-14 2021-07-15 Hanmi Pharmaceutical Co Ltd Formas cristalinas de un compuesto de quinazolina y sus sales clorhidrato.
KR101950942B1 (ko) * 2019-01-28 2019-02-22 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
US20210221792A1 (en) * 2020-01-16 2021-07-22 Hanmi Pharm Co., Ltd. Convergent synthesis of poziotinib derivative
US20220064145A1 (en) * 2020-08-28 2022-03-03 Hanmi Science Co., Ltd. Synthesis of poziotinib derivative

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200813014A (en) * 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
DE602004004811T2 (de) * 2003-09-19 2007-11-22 Astrazeneca Ab Chinazolinderivate
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
KR20080077009A (ko) * 2005-12-12 2008-08-20 베링거 인겔하임 인터내셔날 게엠베하 바이사이클릭 헤테로사이클, 당해 화합물을 함유하는 약제,이의 용도 및 이의 제조방법
TWI377944B (en) * 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
KR20120007059A (ko) * 2009-04-23 2012-01-19 아스트라제네카 아베 4―（3―클로로―2―플루오로―아닐리노）―7―메톡시―6―［［1―（ｎ―메틸카르바모일메틸）―피페리딘―4―일］옥시］퀴나졸린의 제조 방법

Also Published As

Publication number Publication date
DK2763981T3 (da) 2020-03-16
EP2763981A4 (en) 2015-02-25
PT2763981T (pt) 2020-03-25
KR101272613B1 (ko) 2013-06-10
ES2775197T3 (es) 2020-07-24
HUE048798T2 (hu) 2020-08-28
RS60118B1 (sr) 2020-05-29
AU2012319291A1 (en) 2014-05-22
AU2012319291B2 (en) 2016-03-31
IL231911A0 (en) 2014-05-28
CA2850055A1 (en) 2013-04-11
BR112014007718A2 (pt) 2017-04-25
IL231911B (en) 2018-06-28
JP5805880B2 (ja) 2015-11-10
IN2014DN03447A (es) 2015-06-26
HRP20200426T1 (hr) 2020-09-04
WO2013051883A2 (en) 2013-04-11
KR20130037079A (ko) 2013-04-15
RU2563630C1 (ru) 2015-09-20
WO2013051883A3 (en) 2013-06-06
PL2763981T3 (pl) 2020-08-10
CN110003174A (zh) 2019-07-12
MX2014003959A (es) 2014-05-14
EP2763981A2 (en) 2014-08-13
EP2763981B1 (en) 2020-01-08
JP2014528444A (ja) 2014-10-27
CA2850055C (en) 2016-05-17
IL259694A (en) 2018-07-31
IL259694B (en) 2022-04-01
IL291738A (en) 2022-05-01
CN103857672A (zh) 2014-06-11
US8859767B2 (en) 2014-10-14
CN103857672B (zh) 2018-11-30
LT2763981T (lt) 2020-05-25
EP3611172A1 (en) 2020-02-19
CY1122758T1 (el) 2021-03-12
SI2763981T1 (sl) 2020-07-31
US20140275534A1 (en) 2014-09-18
CA2850055E (en) 2013-04-11
BR112014007718B1 (pt) 2022-02-22

Similar Documents

Publication Publication Date Title
MX348815B (es) Metodo para preparar clorhidrato de 1-(4-(4-(3,4-dicloro-2-fluorof enilamino)-7-metoxiquinazolin-6-iloxi)piperidin-1-il)-prop-2-en-1 -ona e intermediarios usados en el mismo.
CO6710911A2 (es) ((r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino.
HRP20190398T1 (hr) Čvrsti oblik (s)-3-(4-((4-morfolinometil)benzil)oksi)-1-oksoizoindolin-2-il)piperidin-2,6-dion hidroklorida
MY169233A (en) Solid forms of an epidermal growth factor receptor kinase inhibitor
IL220155B (en) History of 2, 4-(phenyl-amine-)di-converted pyrimidines for use as kinase inhibitors
RS57210B1 (sr) 2-amino-6-fluoro-n-(5-fluoro-4-(4-(4-(oksetan-3-il)piperazin-1-karbonil)piperidin-1-il)piridin-3-il)pirazolo[1,5alfa]pirimidin-3-karboksamid kao inhibitor atr kinaze
EP2484678A4 (en) SUBSTITUTED 4- (ANILINO) DERIVATIVES QUINAZOLINE AS TYROSINE KINASE INHIBITORS
EP2566477A4 (en) AMINO-QUINOLINES AS KINASE INHIBITORS
PH12014502037A1 (en) Salts of an epidermal growth factor receptor kinase inhibitor
UY31947A (es) Procedimiento mejorado para la preparacion de 2-trifluorometil-5-(1-substituido)alquilpiridina
MY157319A (en) Inhibitors of protein tyrosine kinase activity
EP2521555A4 (en) METHOD AND COMPOSITIONS FOR INCREASING SENSITIVITY AGAINST TYROSINE KINASE INHIBITORS
IL267303B (en) Method for the production of -7-(3,4-dichloro-2-fluorophenylamino)-4)-4)-1 methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one
WO2010099364A3 (en) Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
MX2014004603A (es) Formas de dosificacion solidas de 2-amino-3-(4-(2-amino-6-((r)-1-( 4-cloro-2-(3-metil-1h-pirazol-1-il)fenil)-2,2,2-trifluoroetoxi)pi rimidin-4-il)fenil) propanoato de (s)-etilo.
GB2514285A (en) Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
EA201100683A1 (ru) Полиморфные формы 5-этокси-2-[2-(морфолино)этилтио]бензимидазол дигидрохлорида и способы их получения
NZ737572A (en) Intermediate compounds for the preparation of bipiperidine-2-one compounds
SI2137184T1 (sl) IMIDAZO(1,2-a)PIRIDINSKE SPOJINE KOT INHIBITORJI RECEPTORSKE TIROZINSKE KINAZE

Legal Events

Date Code Title Description
FG Grant or registration